Fundraising FoxArtiva Biotherapeutics
San Diego, US · Founded 2019 · 6 known investors
Find your way into Artiva Biotherapeutics
Sign up to see every warm intro you have to Artiva Biotherapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Artiva Biotherapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Artiva Bio is a clinical-stage biotechnology company developing NK cell-based therapies for autoimmune diseases, designed to be manufactured at scale and delivered in community settings. The company's lead product, AlloNK, combines natural killer cells with B-cell targeted monoclonal antibodies to achieve deep B-cell depletion for disease remission.
Founders & leadership
Board
Investors · 6
How we know: 5AM Ventures's portfolio page · a partner's Signal profile · board seat on SEC Form D · Not right? Tell us
How we know: RA Capital's portfolio page · board seat on SEC Form D · Not right? Tell us
How we know: a partner's Signal profile · the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$163.4M disclosed across 2 rounds · 2020–2021
▶$120MraisedApr 2021 · 27 investors · BiotechnologyRule 506(b)
- Jennifer BushExecutive Officer
- Yong-Jun HuhDirector
- Thomas J. FarrellExecutive Officer
- Yu-Kyeong HwangDirector
- Fred AslanExecutive Officer, Director
- Jason LittenExecutive Officer
- Esther van den BoomExecutive Officer
- Bong KohDirector
- Laura StoppelDirector
- Brian DanielsDirector
- Peter FlynnExecutive Officer
- Yvonne YamanakaDirector
- Offering amount
- $120M
- Amount sold
- $120M
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$43.4MraisedJul 2020 · 8 investors · BiotechnologyRule 506(b)
- Yu-Kyeong HwangDirector
- Yvonne YamanakaDirector
- Laura StoppelDirector
- Jason LittenExecutive Officer
- Peter FlynnExecutive Officer
- Esther van den BoomExecutive Officer
- Brian DanielsDirector
- Yong-Jun HuhDirector
- Thomas J. FarrellExecutive Officer, Director
- Offering amount
- $78.4M
- Amount sold
- $43.4M
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Artiva Biotherapeutics do?
- Artiva Bio is a clinical-stage biotechnology company developing NK cell-based therapies for autoimmune diseases, designed to be manufactured at scale and delivered in community settings. The company's lead product, AlloNK, combines natural killer cells with B-cell targeted monoclonal antibodies to achieve deep B-cell depletion for disease remission.
- Who are Artiva Biotherapeutics's investors?
- Artiva Biotherapeutics's investors include 5AM Ventures, EcoR1 Capital, RA Capital, venBio Partners, Wellington Management, venBio Global Strategic.
- How much funding has Artiva Biotherapeutics raised?
- Artiva Biotherapeutics has disclosed $163.4M raised across 2 rounds.
- Where is Artiva Biotherapeutics headquartered?
- Artiva Biotherapeutics is headquartered in San Diego, US.